ULTRAGENYX PHARMACEUTICAL IN's ticker is RARE and the CUSIP is 90400D108. A total of 237 filers reported holding ULTRAGENYX PHARMACEUTICAL IN in Q1 2022. The put-call ratio across all filers is 2.14 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,657,761 | -87.6% | 46,501 | -84.0% | 0.00% | -100.0% |
| Q2 2023 | $13,376,916 | -41.6% | 289,983 | -49.2% | 0.00% | -40.0% |
| Q1 2023 | $22,889,721 | +68.0% | 570,816 | +94.1% | 0.01% | +66.7% |
| Q4 2022 | $13,624,541 | +4.3% | 294,076 | -6.7% | 0.00% | 0.0% |
| Q3 2022 | $13,058,000 | -79.3% | 315,306 | -70.2% | 0.00% | -81.2% |
| Q2 2022 | $63,084,000 | -34.8% | 1,057,403 | -20.6% | 0.02% | -20.0% |
| Q1 2022 | $96,725,000 | -21.0% | 1,331,932 | -8.5% | 0.02% | -20.0% |
| Q4 2021 | $122,430,000 | -9.3% | 1,455,947 | -2.7% | 0.02% | -10.7% |
| Q3 2021 | $134,911,000 | -24.4% | 1,495,850 | -20.1% | 0.03% | -30.0% |
| Q2 2021 | $178,559,000 | +61.1% | 1,872,679 | +92.3% | 0.04% | +53.8% |
| Q1 2021 | $110,867,000 | +43.9% | 973,713 | +74.9% | 0.03% | +30.0% |
| Q4 2020 | $77,065,000 | +103.0% | 556,710 | +20.5% | 0.02% | +100.0% |
| Q3 2020 | $37,971,000 | -29.6% | 461,987 | -33.0% | 0.01% | -44.4% |
| Q2 2020 | $53,927,000 | -26.6% | 689,420 | -58.3% | 0.02% | -45.5% |
| Q1 2020 | $73,497,000 | +13.7% | 1,654,208 | +9.3% | 0.03% | +17.9% |
| Q4 2019 | $64,635,000 | +165.0% | 1,513,342 | +165.5% | 0.03% | +154.5% |
| Q3 2019 | $24,387,000 | -30.0% | 570,046 | +3.9% | 0.01% | -31.2% |
| Q2 2019 | $34,834,000 | -49.2% | 548,566 | -44.5% | 0.02% | -52.9% |
| Q1 2019 | $68,609,000 | +4728.2% | 989,172 | +2927.5% | 0.03% | – |
| Q4 2018 | $1,421,000 | -92.2% | 32,673 | -86.4% | 0.00% | -100.0% |
| Q3 2018 | $18,316,000 | -52.1% | 239,921 | -51.7% | 0.01% | -57.9% |
| Q2 2018 | $38,202,000 | +52.8% | 496,972 | +1.4% | 0.02% | +46.2% |
| Q1 2018 | $25,000,000 | +79.9% | 490,279 | +63.7% | 0.01% | +62.5% |
| Q4 2017 | $13,893,000 | +544.1% | 299,560 | +639.9% | 0.01% | +300.0% |
| Q3 2017 | $2,157,000 | +48.0% | 40,489 | +72.7% | 0.00% | +100.0% |
| Q2 2017 | $1,457,000 | +41.6% | 23,443 | +54.4% | 0.00% | 0.0% |
| Q1 2017 | $1,029,000 | -10.3% | 15,181 | -6.9% | 0.00% | 0.0% |
| Q4 2016 | $1,147,000 | -36.8% | 16,307 | -36.3% | 0.00% | -50.0% |
| Q3 2016 | $1,815,000 | -92.5% | 25,584 | -93.3% | 0.00% | -93.3% |
| Q1 2016 | $24,060,000 | +156.2% | 380,035 | +354.0% | 0.03% | +200.0% |
| Q4 2015 | $9,392,000 | +70.7% | 83,716 | +46.5% | 0.01% | +100.0% |
| Q3 2015 | $5,503,000 | -70.5% | 57,142 | -68.6% | 0.01% | -68.8% |
| Q2 2015 | $18,654,000 | -51.7% | 182,183 | -70.7% | 0.02% | -56.8% |
| Q1 2015 | $38,587,000 | +135.8% | 621,473 | +66.7% | 0.04% | +131.2% |
| Q4 2014 | $16,361,000 | +38.5% | 372,855 | +78.6% | 0.02% | +33.3% |
| Q3 2014 | $11,815,000 | +27.4% | 208,743 | +1.0% | 0.01% | +9.1% |
| Q2 2014 | $9,273,000 | +261.0% | 206,575 | +293.1% | 0.01% | +266.7% |
| Q1 2014 | $2,569,000 | – | 52,552 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| GREAT POINT PARTNERS LLC | 727,426 | $25,932,737 | 4.72% |
| RTW INVESTMENTS, LP | 5,405,089 | $192,691,423 | 4.07% |
| First Light Asset Management, LLC | 1,125,032 | $40,107,391 | 3.81% |
| CHI Advisors LLC | 215,000 | $7,664,750 | 3.04% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 250,052 | $8,914,354 | 3.00% |
| SPHERA FUNDS MANAGEMENT LTD. | 259,135 | $9,238,163 | 1.68% |
| Rock Springs Capital Management LP | 1,476,441 | $52,635,122 | 1.41% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 679,459 | $24,222,713 | 1.31% |
| Privium Fund Management B.V. | 115,241 | $4,108,341 | 1.22% |
| SECTOR GAMMA AS | 115,166 | $4,105,668 | 1.05% |